|
|
|
| Effect of Loratadine combined with Montelukast Sodium on Serum ICAM-1 ECP EOS and CSF in Patients with Allergic Rhinitis |
| LIU Yijun, ZENG Bangbing, ZENG Lang |
| Guang'an People's Hospital, Sichuan Guang'an 638000, China |
|
|
|
|
Abstract Objective: To investigate the effects of loratadine and montelukast on serum levels of ICAM-1, ECP, EOS and CSF in patients with allergic rhinitis. Methods: 104 cases of allergic rhinitis patients were from August 2013 to October to 2015 period in our hospital clinical cases, by drawing lots were randomly divided into the control group and the experimental group, 52 cases in each group. The control group received oral loratadine treatment, and the experimental group was treated with montelukast on the basis of the control group. The clinical efficacy, the levels of serum ICAM-1, ECP, EOS, CSF, nasal symptoms, VAS score and adverse reactions before and after treatment were compared between the two groups. Results: After treatment, the clinical efficacy of the experimental group (90.38%) was higher than that of the control group (80.77%), and the difference was statistically significant (P<0.05). There was no significant difference in serum ICAM-1, ECP, EOS and CSF levels between the two groups before treatment (P<0.05). After treatment, the VAS scores of the experimental group were significantly lower than those of the control group [(6.69 +2.08) VS (7.86 +2.69), (374.58 +69.83) VS (468.46 +80.53), (3.02 +0.88) VS (3.91 +0.89), (16.69 +3.47) VS (29.58 +5.73)]. After treatment, the nasal symptoms of the two groups were significantly lower than those of the control group. The adverse reactions in the experimental group were significantly lower than those in the control group, and there was no difference between the two groups (P>0.05). Conclusion: Loratadine combined with montelukast sodium has a definite therapeutic effect on allergic rhinitis. It can reduce the levels of serum ICAM-1, ECP, EOS and CSF, improve clinical symptoms, and is worthy of clinical application.
|
|
|
|
|
|
[1] 李昕蓉,张勤修,刘洋,等.面部穴位埋线对变应性鼻炎最轻持续性炎症调节机制的研究[J].时珍国医国药,2015,26(8):2043~2047.
[2] 李娟,程杰,何艳.鼻腔冲洗联合糠酸莫米松鼻喷雾剂治疗变应性鼻炎的疗效观察[J].重庆医学,2016,45(25):3506~3507.
[3] 凌云,杨春悦,杨红梅.氮卓斯汀鼻喷剂联合地氯雷他定治疗过敏性鼻炎65例的疗效评价[J].中国免疫学杂志,2014,30(06):828~830.
[4] 王任霞,张春晖.孟鲁司特钠联合布地奈德鼻喷雾剂和枸地氯雷他定治疗中-重度持续性变应性鼻炎的临床疗效分析[J].临床耳鼻咽喉头颈外科杂志,2015,29(23):2041~2043.
[5] 视觉模拟评分法[J].临床和实验医学杂志,2013,12(23):1925.
[6] 侯明月.氯雷他定、孟鲁司特钠治疗季节性变应性鼻炎疗效对比观察[J].山东医药,2016,56(26):99~101.
[7] 王华,倪青,高宇哲,等.NF-κBp65、ICAM-1和sICAM-1在浆细胞性乳腺炎中的表达及意义[J].广东医学,2016,37(21):3208~3211.
[8] 陈益丹,金肖青,俞迈红,等.针罐结合对中重度变应性鼻炎血清Eotaxin、ICAM-1及ECP表达的影响[J].中华中医药学刊,2016,34(1):170~173.
[9] 侯穗波,梁桂珍,罗媚旦,等.变应性鼻炎特异性免疫治疗对白细胞介素-4、白细胞介素-5和白细胞介素-13影响的动态观察[J].中国现代医学杂志,2015,25(4):34~36. |
|
|
|
2019, Vol. 25 
